Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase and α-amylase inhibitors from seed oil: A review of liposoluble substance to treat diabetes.
|
26854322 |
2017 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
α-Glucosidase inhibitors (AGIs) have been reported for their clinical potential against postprandial hyperglycemia, which is responsible for the risks associated with diabetes mellitus 2 and cardiovascular diseases (CVDs).
|
28745232 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-glucosidase is a therapeutic target for diabetes mellitus (DM) and α-glucosidase inhibitors play a vital role in the treatments for the disease.
|
29506517 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase enzymes contribute to the digestion of starch into glucose and are thus attractive therapeutic targets for diabetes.
|
29548257 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase is a critical enzyme associated with diabetes mellitus, and the inhibitors of the enzyme play important roles in the treatment of the disease.
|
30227201 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase plays an important role in carbohydrate metabolism and is therefore an attractive therapeutic target for the treatment of diabetes, obesity and other related complications.
|
30282319 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase inhibitors have been approved as therapeutic agents for diabetes.
|
31555798 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
α-Glucosidase and its inhibitors play a key role in diagnosis and treatment of diabetes.
|
31670357 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accordingly, nutritional composition, the content of phytochemical antioxidants, and the inhibitory ability of key enzymes with impacts on obesity and diabetes (α-glucosidase and pancreatic lipase) or on arterial pressure (angiotensin-I converting enzyme), were evaluated.
|
30274353 |
2018 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
After adjusting for age, gender, ethnicity, body mass index, smoking status, socioeconomic status, hypertension, hyperlipidaemia, diabetes, duration of diabetes and cardiovascular disease, ACE inhibitors (OR=1.27; 95% CI 1.05 to 1.55), fibrates (OR=1.57; 95% CI 1.05 to 2.35), alpha-glucosidase inhibitors (AGIs) (OR=1.85; 95% CI 1.13 to 3.02) and insulin (OR=1.80; 95% CI 1.11 to 2.93) were significantly associated with the presence of cortical cataract.
|
31272959 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-α-glucosidase (AAG) compounds have received great attention due to their potential use in treating diabetes.
|
30769933 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
As the close correlation between α-glucosidase inhibitors and the treatment of diabetes, in combination with capillary electrophoresis (CE), a method was developed to screen α-glucosidase inhibitors from traditional Chinese medicines (TCMs) by immobilizing α-glucosidase on magnetic nanoparticles.
|
28107971 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
As the most common drugs for diabetes mellitus, synthetic compounds can also be classified into several categories according to their working mechanisms, such as insulin secretion promotor agents, insulin sensitizer agents, α-glucosidase inhibitors, and so forth.
|
31214029 |
2019 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase).
|
31808389 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Cratoxylum cochinchinense displayed significant inhibition against protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase, both of which are key target enzymes to attenuate diabetes and obesity.
|
29306546 |
2018 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
EAE was the most effective enzyme inhibitor, exhibiting the highest inhibition against some enzymes linked to Alzheimer's disease (cholinesterases), diabetes mellitus (α-glucosidase and α-amylase) and hyperpigmentation problems (tyrosinase).
|
30466026 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Enzyme inhibitory potential was assessed against key enzymes linked to global health problems, namely neurodegenerative diseases (acetylcholinesterase), pigmentation (tyrosinase), and diabetes (α-amylase and α-glucosidase).
|
29169111 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the possibility of developing in diabetics and the significant association between diabetes and infection, the present study was conducted to investigate the influences of tetracycline (TET), kanamycin (KANA), lincomycin (LIN), erythromycin (ERM) and azithromycin (AZM) on α-glucosidase and α-amylase activities with calculating IC<sub>50</sub> and K<sub>i</sub> values.
|
31400388 |
2019 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Glycemic control which can be efficaciously regulated by inhibiting α-glucosidase activity is an effective therapy for diabetes mellitus.
|
29030193 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Gray, and <i>Salvia officinalis</i> L. decoctions were investigated for their health-benefit properties, in particular with respect to antioxidant activity and inhibitory ability towards key enzymes with impact in diabetes and obesity (α-glucosidase, α-amylase and pancreatic lipase).
|
30513773 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Human α-glucosidase is an enzyme involved in the catalytic cleavage of the glucoside bond and involved in numerous functionalities of the organism, as well as in the insurgence of diabetes mellitus 2 and obesity.
|
29421954 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In this work, phenol-rich extracts from 'Cornicabra' and 'Picual' virgin-olive oils (EVOOs) were examined, for the first time, to establish their capacity to inhibit key enzymes involved in Alzheimer's disease (AD) (acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and 5-lipoxygenase (LOX)), major depressive disorder (MDD) and Parkinson's disease (PD) (monoamine oxidases: hMAO-A and hMAO-B respectively), and diabetes mellitus (DM) (α-glucosidase and α-amylase).
|
29579961 |
2018 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased α-glucosidase, PEPCK, GLUT-2 and SGLTs levels with the induction of diabetes considerably lowered with TPSE treatment.
|
30399410 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitory potential against key enzymes involved in diabetes (α-glucosidase and α-amylase), obesity (pancreatic lipase), neurodegenerative diseases (cholinesterases), and hyperpigmentation (tyrosinase) was evaluated.
|
28040595 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Lxn significantly inhibited (p < 0.05) the activity of α-amylase and α-glucosidase and could be of medical and nutritional relevance in the treatment of diabetes.
|
28170007 |
2017 |